AI Tokens
Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Adjustments to Financial Statements

Microsoft Excel

Adjustments to Current Assets

Boston Scientific Corp., adjusted current assets

US$ in millions

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Current assets 5,760 6,317 6,694 4,699 4,003
Adjustments
Add: Allowance for credit losses 109 108 105 74 68
After Adjustment
Adjusted current assets 5,869 6,425 6,799 4,773 4,071

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Between 2018 and 2022, current assets exhibited a trajectory of growth followed by a gradual contraction. Total current assets rose from 4,003 million US$ in 2018 to a peak of 6,694 million US$ in 2020, before declining to 5,760 million US$ by the end of 2022. Adjusted current assets followed an identical directional pattern, peaking in 2020 at 6,799 million US$.

Asset Growth and Volatility
A significant expansion of current assets occurred between 2019 and 2020, with a year-over-year increase of approximately 42%. This peak was followed by a two-year downward trend, resulting in a 14% decrease from the 2020 high to the 2022 year-end balance.
Adjustment Variance Analysis
A consistent positive adjustment is applied to the current assets across the entire period. The absolute value of this adjustment increased steadily from 68 million US$ in 2018 to 109 million US$ in 2022. This indicates a persistent and slightly growing additive factor used in the adjustment process.
Relative Impact of Adjustments
The gap between reported and adjusted current assets remains relatively narrow in proportion to the total asset base. The adjustment represented approximately 1.7% of current assets in 2018 and approximately 1.9% in 2022, suggesting that the adjustments are stable and do not introduce significant volatility into the financial position.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Total Assets

Boston Scientific Corp., adjusted total assets

US$ in millions

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Total assets 32,469 32,229 30,777 30,565 20,999
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1 — — — — 308
Add: Allowance for credit losses 109 108 105 74 68
Less: Deferred tax assets2 3,942 4,142 4,210 4,196 87
After Adjustment
Adjusted total assets 28,636 28,195 26,672 26,443 21,288

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 Deferred tax assets. See details »


An analysis of the asset trajectory from 2018 to 2022 reveals a significant expansion in the balance sheet, characterized by a sharp increase in total assets between 2018 and 2019, followed by a period of steady, moderate growth. Total assets rose from 20,999 million US$ in 2018 to 32,469 million US$ by the end of 2022, representing an overall increase of approximately 54.6%.

Total Asset Growth Trend
The most substantial growth occurred between December 31, 2018, and December 31, 2019, where total assets increased by 9,566 million US$. From 2019 through 2022, the growth rate decelerated, with annual increases remaining relatively stable and incremental.
Adjusted Total Assets Divergence
A notable shift in the relationship between total assets and adjusted total assets occurred in 2019. In 2018, adjusted total assets were slightly higher than total assets by 289 million US$. However, starting in 2019, adjusted total assets became consistently lower than total assets, indicating the application of significant downward adjustments.
Analysis of Adjustment Magnitude
From 2019 to 2022, a persistent gap was observed between the two metrics. The maximum negative adjustment occurred in 2019 at 4,122 million US$, and this variance remained relatively constant through 2022, ending at 3,833 million US$. This suggests a structural adjustment to the asset base that was introduced in 2019 and maintained throughout the subsequent period.
Comparative Growth Rates
While both metrics trended upward, adjusted total assets grew at a slower pace than total assets over the full five-year period. Adjusted total assets increased from 21,288 million US$ in 2018 to 28,636 million US$ in 2022, reflecting a total growth of approximately 34.5%.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Current Liabilities

Boston Scientific Corp., adjusted current liabilities

US$ in millions

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Current liabilities 3,803 4,274 3,681 4,866 5,260
Adjustments
Less: Current deferred revenue 220 208 138 144 —
After Adjustment
Adjusted current liabilities 3,583 4,066 3,543 4,722 5,260

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


An analysis of current liabilities from 2018 to 2022 reveals a general downward trajectory, characterized by significant volatility between 2020 and 2022. Total current liabilities decreased from 5,260 million US$ in 2018 to 3,803 million US$ by the end of 2022, representing an overall reduction in short-term obligations over the five-year period.

Liability Trends and Volatility
A substantial contraction in current liabilities occurred between 2018 and 2020, with figures dropping from 5,260 million US$ to a period low of 3,681 million US$. This trend reversed in 2021 as liabilities rose to 4,274 million US$, before declining again to 3,803 million US$ in 2022. Adjusted current liabilities mirrored this movement, reaching their lowest point in 2020 at 3,543 million US$.
Analysis of Adjustments
A divergence between reported current liabilities and adjusted current liabilities emerged after 2018. While no adjustment was recorded in 2018, a consistent downward adjustment was applied from 2019 onward. The magnitude of these adjustments has expanded over time, increasing from 144 million US$ in 2019 to 220 million US$ in 2022.
Comparative Variance
The gap between reported and adjusted figures widened progressively. By 2022, adjusted current liabilities were approximately 5.8% lower than the reported current liabilities. This widening variance suggests a growing reliance on adjustments to refine the presentation of short-term obligations for analytical purposes.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Total Liabilities

Boston Scientific Corp., adjusted total liabilities

US$ in millions

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Total liabilities 14,896 15,608 15,451 16,688 12,273
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — — 308
Less: Deferred tax liabilities2 144 310 330 595 328
Less: Deferred revenue 509 484 395 400 —
After Adjustment
Adjusted total liabilities 14,243 14,814 14,726 15,693 12,253

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Deferred tax liabilities. See details »


An analysis of the liability structure from 2018 to 2022 reveals a significant increase in obligations during 2019, followed by a period of relative stabilization and a subsequent gradual decline. Total liabilities rose from US$ 12,273 million in 2018 to a peak of US$ 16,688 million in 2019, before decreasing to US$ 14,896 million by the end of 2022.

Liability Variance Trends
A widening gap between total and adjusted liabilities is observed beginning in 2019. The variance grew from a nominal US$ 20 million in 2018 to US$ 995 million in 2019, indicating a substantial adjustment to reported obligations during that fiscal year.
Trajectory of Adjusted Liabilities
Adjusted total liabilities mirrored the general movement of total liabilities but remained consistently lower. After peaking at US$ 15,693 million in 2019, the adjusted figure trended downward to US$ 14,243 million by December 31, 2022.
Analysis of Adjustment Magnitude
Between 2020 and 2022, the difference between total and adjusted liabilities remained significant, fluctuating between US$ 653 million and US$ 794 million. This suggests the presence of persistent accounting adjustments or specific liability exclusions that remained relevant throughout the latter half of the observed period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Stockholders’ Equity

Boston Scientific Corp., adjusted stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Stockholders’ equity 17,573 16,622 15,326 13,877 8,726
Adjustments
Less: Net deferred tax assets (liabilities)1 3,799 3,833 3,734 3,601 (241)
Add: Allowance for credit losses 109 108 105 74 68
Add: Deferred revenue 509 484 395 400 —
After Adjustment
Adjusted stockholders’ equity 14,392 13,381 12,092 10,750 9,035

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Net deferred tax assets (liabilities). See details »


A consistent upward trajectory is observed in both stockholders' equity and adjusted stockholders' equity from 2018 through 2022. The total stockholders' equity grew from 8,726 million US$ in 2018 to 17,573 million US$ in 2022, reflecting a substantial expansion of the company's book value over the five-year period.

Growth Patterns in Stockholders' Equity
The most significant increase in stockholders' equity occurred between 2018 and 2019, where the value rose by 5,151 million US$. Following this surge, the equity continued to grow at a more moderated but steady pace, adding approximately 1,300 to 1,400 million US$ annually between 2019 and 2021, before a smaller increase of 951 million US$ was recorded in 2022.
Adjusted Stockholders' Equity Trends
Adjusted stockholders' equity followed a similar growth trend, increasing from 9,035 million US$ in 2018 to 14,392 million US$ in 2022. Unlike the reported equity, the growth in adjusted equity was more linear, with annual increases ranging between 1,011 million US$ and 1,715 million US$ throughout the period.
Analysis of Equity Divergence
A notable shift in the relationship between reported and adjusted equity occurred between 2018 and 2019. In 2018, adjusted stockholders' equity exceeded reported equity by 309 million US$. However, starting in 2019, this relationship reversed, with reported equity significantly exceeding adjusted equity. From 2019 to 2022, a consistent gap emerged, with reported equity remaining approximately 3.1 to 3.2 billion US$ higher than the adjusted figure, suggesting a persistent adjustment factor impacting the equity valuation.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Capitalization Table

Boston Scientific Corp., adjusted capitalization table

US$ in millions

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Current debt obligations 20 261 13 1,416 2,253
Long-term debt 8,915 8,804 9,130 8,592 4,803
Total reported debt 8,935 9,065 9,143 10,008 7,056
Stockholders’ equity 17,573 16,622 15,326 13,877 8,726
Total reported capital 26,508 25,687 24,469 23,885 15,782
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — — 308
Add: Current operating lease liabilities (in Other current liabilities)2 61 71 70 67 —
Add: Long-term operating lease liabilities3 347 389 401 276 —
Adjusted total debt 9,343 9,525 9,614 10,351 7,364
Adjustments to Equity
Less: Net deferred tax assets (liabilities)4 3,799 3,833 3,734 3,601 (241)
Add: Allowance for credit losses 109 108 105 74 68
Add: Deferred revenue 509 484 395 400 —
Adjusted stockholders’ equity 14,392 13,381 12,092 10,750 9,035
After Adjustment
Adjusted total capital 23,735 22,906 21,706 21,101 16,399

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Current operating lease liabilities (in Other current liabilities). See details »

3 Long-term operating lease liabilities. See details »

4 Net deferred tax assets (liabilities). See details »


The capitalization structure from 2018 to 2022 demonstrates a significant expansion in total capital and a strategic shift toward a more equity-heavy funding base. While reported total capital grew from 15,782 million US$ to 26,508 million US$, the composition of this capital evolved, characterized by a peak in debt obligations in 2019 followed by a period of consistent deleveraging and equity accumulation.

Debt Obligations and Deleveraging Trends
Reported debt experienced a sharp increase between 2018 and 2019, rising from 7,056 million US$ to 10,008 million US$. Following this peak, a sustained downward trend occurred, with debt levels declining to 8,935 million US$ by the end of 2022. Adjusted debt figures mirror this trajectory, peaking at 10,351 million US$ in 2019 and descending to 9,343 million US$ in 2022, indicating a consistent effort to reduce long-term liabilities.
Equity Growth and Capital Strengthening
Stockholders' equity exhibited robust and uninterrupted growth throughout the analyzed period. Reported equity more than doubled, increasing from 8,726 million US$ in 2018 to 17,573 million US$ in 2022. This trajectory indicates a substantial increase in the company's net asset value and a reduced reliance on external borrowing to fund operations and growth.
Analysis of Capitalization Adjustments
A divergence between reported and adjusted figures is evident across all categories. Adjusted total debt is consistently higher than reported debt, suggesting the inclusion of lease obligations or other debt-like liabilities. Conversely, adjusted stockholders' equity is lower than reported equity from 2019 onwards, falling from a reported 17,573 million US$ to an adjusted 14,392 million US$ by 2022. These adjustments result in an adjusted total capital figure that is lower than the reported total capital for the majority of the period, providing a more conservative view of the firm's financial position.
Overall Capitalization Shift
The transition from 2018 to 2022 reflects a fundamental change in the debt-to-equity mix. In 2018, debt and equity were relatively balanced. By 2022, equity became the dominant component of the capital structure, which enhances solvency and reduces the financial risk profile associated with fixed interest obligations.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Revenues

Boston Scientific Corp., adjusted net sales

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Net sales 12,682 11,888 9,913 10,735 9,823
Adjustment
Add: Increase (decrease) in deferred revenue 25 89 (5) 27 —
After Adjustment
Adjusted net sales 12,707 11,977 9,908 10,762 9,823

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Net sales exhibited a general upward trajectory between 2018 and 2022, characterized by a period of volatility centered around the 2020 fiscal year. Following a growth phase in 2019, a temporary contraction occurred in 2020, which was subsequently followed by a sustained recovery and acceleration in revenue through 2022.

Revenue Growth Dynamics
Net sales increased from 9,823 million US$ in 2018 to 12,682 million US$ by the end of 2022. The most significant growth surge occurred between 2020 and 2021, where revenue increased by approximately 20%, signaling a robust recovery following the 2020 dip.
Analysis of Revenue Adjustments
The variance between net sales and adjusted net sales remained relatively immaterial relative to total volume throughout the five-year period. While 2018 showed zero variance, subsequent years displayed minor fluctuations. Adjusted net sales were higher than reported net sales in 2019, 2021, and 2022, with the most substantial positive adjustment occurring in 2021 at 89 million US$. Conversely, a slight downward adjustment was noted in 2020.
Correlation Between Reporting Metrics
A high degree of correlation exists between net sales and adjusted net sales, indicating that the adjustments do not fundamentally alter the underlying financial trend. Both metrics consistently reflect the same peaks and troughs, confirming that the adjusted figures maintain the integrity of the primary revenue trajectory.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Reported Income

Boston Scientific Corp., adjusted net income (loss)

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Net income (loss) 698 1,041 (82) 4,700 1,671
Adjustments
Add: Deferred income tax expense (benefit)1 (7) (142) (85) (4,288) (162)
Add: Increase (decrease) in allowance for credit losses 1 3 31 6 —
Add: Increase (decrease) in deferred revenue 25 89 (5) 27 —
Add: Other comprehensive income (loss), net of tax 6 55 (63) 237 91
After Adjustment
Adjusted net income (loss) 723 1,046 (204) 682 1,600

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Deferred income tax expense (benefit). See details »


An analysis of the financial results from 2018 to 2022 reveals significant volatility in both reported and adjusted net income, with a notable divergence occurring in 2019. While both metrics generally follow the same trajectory of recovery and decline, the scale of variance indicates the impact of non-recurring items on the reported figures.

Reported Net Income Volatility
Reported net income experienced extreme fluctuations, peaking in 2019 at 4,700 million US dollars before dropping to a loss of 82 million US dollars in 2020. A subsequent recovery occurred in 2021, reaching 1,041 million US dollars, followed by a moderate decline to 698 million US dollars in 2022.
Adjusted Net Income Trends
Adjusted net income demonstrates a more subdued trend than reported figures. After starting at 1,600 million US dollars in 2018, it declined to 682 million US dollars in 2019 and reached its lowest point in 2020 with a loss of 204 million US dollars. Performance improved in 2021 to 1,046 million US dollars and settled at 723 million US dollars in 2022.
Analysis of Variance
The most substantial discrepancy is observed in 2019, where reported net income exceeded adjusted net income by 4,018 million US dollars, suggesting a significant one-time gain. In contrast, 2021 and 2022 show a high degree of convergence between reported and adjusted figures, indicating that non-recurring adjustments had a minimal impact on profitability during the latter part of the period.
Comparative Performance Cycle
A cyclical pattern is evident across both metrics, characterized by a sharp downturn in 2020 followed by a recovery in 2021. The consistency between the two metrics in the most recent two years suggests a stabilization of the factors affecting net income.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?